Evgenia Preka

Evgenia Preka

Auto-generated profile, based on publicly available information

Evgenia Preka

Centre de Référence MARHEA, Institut Imagine, Néphrologie Pédiatrique, Hôpital Necker Enfants Malades, Université Paris Cité, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ALAlexandre Loupy
Alexandre Loupy
EPEvgenia Preka
Evgenia Preka
XCXiangmei Chen
Xiangmei Chen
HWHaibo Wang
Haibo Wang
JHJianxing He
Jianxing He
KZKang Zhang
Kang Zhang

30 April 2019 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
EPEvgenia Preka
Evgenia Preka
MBMarjolein Bonthuis
Marjolein Bonthuis
JHJerome Harambat
Jerome Harambat
KJKitty J Jager
Kitty J Jager
JGJaap W Groothoff
Jaap W Groothoff
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU
Background: There is no consensus regarding the timing of dialysis therapy initiation for end-stage kidney disease (ESKD) in children. As studies investigating the association between timing of dialysis initiation and clinical outcomes are lacking, we aimed to study this relationship in a cohort of European children who started maintenance dialysis treatment.Methods: We used data on 2963 children from 21 different countries included in the European Society of Pediatric Nephrology/European Renal Association–European Dialysis and Transplant Association Registry who started renal replacement therapy before 18 years of age between 2000 and 2014. We compared two groups according to the estimated glomerular filtration rate (eGFR) at start: eGFR ≥8 mL/min/1.73 m2 (early starters) and eGFR <8 mL/min/1.73 m2 (late starters). The primary outcomes were patient survival and access to transplantation. Secondary outcomes were growth and cardiovascular risk factors. Sensitivity analyses were performed to account for selection- and lead time-bias.Results: The median eGFR at the start of dialysis was 6.1 for late versus 10.5 mL/min/1.73 m2 for early starters. Early starters were older [median: 11.0, interquartile range (IQR): 5.7–14.5 versus 9.4, IQR: 2.6–14.1 years]. There were no differences observed between the two groups in mortality and access to transplantation at 1, 2 and 5 years of follow-up. One-year evolution of height standard deviation scores was similar among the groups, whereas hypertension was more prevalent among late initiators. Sensitivity analyses resulted in similar findings.Conclusions: We found no evidence for a clinically relevant benefit of early start of dialysis in children with ESKD. Presence of cardiovascular risk factors, such as high blood pressure, should be taken into account when deciding to initiate or postpone dialysis in children with ESKD, as this affects the survival.

3 September 2020 in Clinical Chemistry
Verified
Journal Article
Closed access
EPEvgenia Preka
Evgenia Preka
DEDrew Ellershaw
Drew Ellershaw
NCNatalie Chandler
Natalie Chandler
HAHelena Ahlfors
Helena Ahlfors
HSHelen Spencer
Helen Spencer
SMStephen D Marks
Stephen D Marks
Background: The use of cell-free DNA (cfDNA) as a noninvasive biomarker to detect allograft damage is expanding rapidly. However, quantifying the low fraction of donor-derived cfDNA (ddcfDNA) is challenging and requires a highly sensitive technique. ddcfDNA detection through unique donor single nucleotide polymorphisms (SNPs) is a recent new approach, however there are limited data in pediatric solid organ transplant (SOT) recipients. Methods: We developed an assay using a combination of 61 SNPs to quantify the ddcfDNA accurately using a custom R script to model for both the patient and donor genotypes requiring only a single sample from the allograft recipient. Performance of the assay was validated using genomic DNA (gDNA), cfDNA and donor samples where available. Results: The R “genotype-free” method gave results comparable to when using the known donor genotype. applicable to both related and unrelated pairs and can reliably measure ddcfDNA (limit of blank, below 0.12%; limit of detection, above 0.25%; limit of quantification 0.5% resulting in 84% accuracy). 159 pediatric SOT recipients (kidney, heart, and lung) were tested without the need for donor genotyping. Serial sampling was obtained from 82 patients. Conclusion: We have developed and validated a new assay to measure the fraction of ddcfDNA in the plasma of pediatric SOT recipients. Our method can be applicable in any donor-recipient pair without the need for donor genotyping and can provide results in 48 h at a low cost. Additional prospective studies are required to demonstrate its clinical validity in a large cohort of pediatric SOT recipients.

15 August 2019 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
EPEvgenia Preka
Evgenia Preka
LRLesley Rees
Lesley Rees

15 October 2020 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
EPEvgenia Preka
Evgenia Preka
RSRukshana Shroff
Rukshana Shroff
LSLynsey Stronach
Lynsey Stronach
FCFrancis Calder
Francis Calder
CSConstantinos J. Stefanidis
Constantinos J. Stefanidis

22 January 2020 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
EPEvgenia Preka
Evgenia Preka
MWMandy Wan
Mandy Wan
KPKaren L Price
Karen L Price
DLDavid A Long
David A Long
HAHelen Aitkenhead
Helen Aitkenhead
RSRukshana Shroff
Rukshana Shroff
Background: Total serum 25-hydroxyvitamin D [25(OH)D] is considered the best marker of vitamin D status and used routinely in clinical practice. However, 25(OH)D is predominantly bound to vitamin D-binding protein (VDBP), and it has been reported that the free-25(OH)D and 25(OH)D loosely bound to albumin fraction correlates better with clinical outcomes. Methods: We assessed total-25(OH)D, measured free-25(OH)D, and calculated free-25(OH)D and their relationship with VDBP and biomarkers of mineral metabolism in 61 children (22 CKD 2–3, 18 dialysis, and 21 post-transplant). Results: Total-25(OH)D concentrations were comparable across the three groups (p = 0.09), but free- and bioavailable-25(OH)D (free- and albumin-25(OH)D) were significantly lower in the transplant group (both: p = 0.01). Compared to CKD and dialysis patients, the transplant group had significantly higher VDBP concentrations (p = 0.03). In all three groups, total-25(OH)D concentrations were positively associated with measured free-, calculated free-, and bioavailable-25(OH)D. Multivariable regression analysis showed that total-25(OH)D was the only predictor of measured free-25(OH)D concentrations in the dialysis group (β = 0.9; R2 = 90%). In the transplant group, measured free-25(OH)D concentrations were predicted by both total-25(OH)D and VDBP concentrations (β = 0.6, − 0.6, respectively; R2 = 80%). Correlations between parathyroid hormone with total-25(OH)D and measured and calculated free-25(OH)D were only observed in the transplant group (all: p < 0.001). Conclusions: In transplanted patients, VDBP concentrations were significantly higher compared to CKD and dialysis patients, and consequently, free-25(OH)D concentrations were lower, despite a comparable total-25(OH)D concentration. We suggest that free-25(OH)D measures may be required in children with CKD, dialysis, and transplant, with further research required to understand its association with markers of mineral metabolism.